Lupin gains on U.S. approval for eye drop generic

Reuters

Reuters Market Eye - Shares in Lupin Ltd (NSI:LUPIN.NS - News) gain 3.2 percent after the company got the final approval from the U.S. Food and Drug Administration for a generic version of eye drop Gatifloxacin on Friday, according to the web site of the U.S. regulator.

Gatifloxacin treats conjunctivitis, or more commonly called pink eye, and is produced by Allergan Inc (NYS:AGN - News).

A Lupin spokesman was not immediately reachable for comment.

(Reporting by Abhishek Vishnoi)

Rates

View Comments (0)